Profile
Daniel-Adriano Silva was the founder who started Neoleukin Therapeutics, Inc. in 2003, where he held the title of Vice President-Research until 2021.
He obtained an undergraduate degree from Universidad Nacional Autónoma de México.
Former positions of Daniel-Adriano Silva
| Companies | Position | End |
|---|---|---|
| NEUROGENE INC. | Founder | 2021-02-28 |
Training of Daniel-Adriano Silva
| Universidad Nacional Autónoma de México | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Daniel-Adriano Silva
